The use of surrogate markers in the antiretroviral treatment of HIV-1 infection

Hill, A.M.

Citation for published version (APA):
Acknowledgements
ACKNOWLEDGEMENTS

1988-1992
Thanks first of all to Tony Pinching who taught me in the early days. Those tutorials in his tiny office in St Mary's hospital in the late 1980's, with complex immunology mixed with Tony's pipe, are etched in my mind. He was the man who said "get the methods right and the results will come themselves". One day I hope this works out! Professor Roy Anderson was my other original tutor and helped teach me non-trivial, non-linear epidemiology and statistics, and pulled me down a peg or two when the theories became a bit too off the wall.

Then thanks to the clinical team at St Mary's - Mark Gompels, Theresa Ekong and Barry Peters, for all their advice on the clinical reality of HIV/AIDS before we had good treatments. Those days on the ward rounds in 1989-91, when AZT was first being introduced but not working for long, were a struggle for everyone. The early work on CD4 counts and other markers of progression was a great introduction to the years ahead.

1992-1999
Hugh McDade was the clinical director for Glaxo in the early 1990's, and greeted me with the poetically Scottish words "fe fi fo fum, I smell the blood of a statistician". Robert Burns would shudder in his grave! There were many people in the team which developed 3TC, from a nucleoside monotherapy with 4 weeks of activity to a useful part of HAART. Phil Collis was always one to keep his cool, even when having to deal with the CAESAR trial interim analysis. Will Sawyer was a very smart statistician who worked on the meta-analysis of clinical endpoints in the 3TC trials. Ralph DeMasi worked with me on the analyses of surrogate marker validation in 1995-1997, presenting the final data at the FDA.

There were many clinicians who also were involved with the surrogate marker validation project, as part of the 3TC trials. Clive Loveday performed the analysis of HIV RNA from the NUCB2001 trial, using one of the first PCR tests. This allowed us to show the correlation between HIV RNA, CD4 count and progression to AIDS for these 3TC treated patients. Schlomo Staszeswski was the principal investigator for the NUCB3002 trial - data from this trial were combined with others, to correlate HIV RNA and CD4 counts with clinical progression. Milos Opravil collaborated on the analysis of baseline HIV RNA levels as a predictor of response to double NRTI treatment. Julio Montaner was one of the principal investigators from the CAESAR trial, from which some of the main analyses of HIV RNA as a surrogate marker were produced.

Thanks also to David Cooper - a voice of hope in the darkest days of 1993 when none of the treatments seemed to be working, and then later on with the PILLR and MITOX trials, where the theories of lipodystrophy were turned on their heads.

And to Joep Lange, for his sound advice over the years, particularly with the analyses of HIV RNA in the AVANTI trials, and work in developing countries.

1999-2002
Thanks to Jens Lundgren for his help in unravelling fact from fiction with the MaxCmin trials, and to the pharmacologists and virologists who helped in the work on Cmin/IC50 ratios.

Thanks to Jim Scott and the people at Meditech, for their help in formatting and publishing this thesis. Also to Ferdinand Wit for helping me through the PhD process.